In contrast, an open-label, real-world study conducted in the UK with 298 patients with T1D who had been receiving insulin Gla-300 for 6 months, demonstrated a mean significant reduction in HbA1c of 0.4% [22]. This evidence concerns the gene INS and type 1 diabetes mellitus.